143 related articles for article (PubMed ID: 38008504)
21. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Quality of Life, Sexual Quality of Life, and Pain Symptoms in Deep Infiltrating Endometriosis Patients With or Without Associated Adenomyosis and the Influence of a Flexible Extended Combined Oral Contraceptive Regimen: Results of a Prospective, Observational Study.
Alcalde AM; Martínez-Zamora MÁ; Gracia M; Ros C; Rius M; Castelo-Branco C; Carmona F
J Sex Med; 2022 Feb; 19(2):311-318. PubMed ID: 34974988
[TBL] [Abstract][Full Text] [Related]
23. Dienogest: a new therapeutic agent for the treatment of endometriosis.
Harada T; Taniguchi F
Womens Health (Lond); 2010 Jan; 6(1):27-35. PubMed ID: 20001868
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of endometriosis among patients with adenomyosis and/or myoma uteri scheduled for a hysterectomy.
Naphatthalung W; Cheewadhanaraks S
J Med Assoc Thai; 2012 Sep; 95(9):1136-40. PubMed ID: 23140029
[TBL] [Abstract][Full Text] [Related]
25. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
26. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
Kitawaki J; Kusuki I; Yamanaka K; Suganuma I
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):212-6. PubMed ID: 21474232
[TBL] [Abstract][Full Text] [Related]
27. Focal adenomyosis (intramural endometriotic cyst) in a very young patient - differential diagnosis with uterine fibromatosis.
Manta L; Suciu N; Constantin A; Toader O; Popa F
J Med Life; 2016; 9(2):180-2. PubMed ID: 27453751
[TBL] [Abstract][Full Text] [Related]
28. Long-term use of dienogest for the treatment of primary and secondary dysmenorrhea.
Osuga Y; Hayashi K; Kanda S
J Obstet Gynaecol Res; 2020 Apr; 46(4):606-617. PubMed ID: 32050307
[TBL] [Abstract][Full Text] [Related]
29. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Hassanin AI; Youssef AA; Yousef AM; Ali MK
Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
[TBL] [Abstract][Full Text] [Related]
30. Neonatal uterine bleeding as a precursor to endometriosis in adulthood.
Tandashvili L; Gvenetadze A; Iremadze L; Tanos V
Afr J Reprod Health; 2022 Aug; 26(8):83-88. PubMed ID: 37585034
[TBL] [Abstract][Full Text] [Related]
31. Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study.
Cho B; Roh JW; Park J; Jeong K; Kim TH; Kim YS; Kwon YS; Cho CH; Park SH; Kim SH
Reprod Sci; 2020 Mar; 27(3):905-915. PubMed ID: 32052358
[TBL] [Abstract][Full Text] [Related]
32. Relief of uterine bleeding by cyclic administration of dienogest for endometriosis.
Yanase T; Tsuneki I; Tamura M; Kurabayashi T
Gynecol Endocrinol; 2014 Nov; 30(11):804-7. PubMed ID: 25060125
[TBL] [Abstract][Full Text] [Related]
33. Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia.
Andreeva E; Absatarova Y
Int J Gynaecol Obstet; 2020 Dec; 151(3):347-354. PubMed ID: 32815156
[TBL] [Abstract][Full Text] [Related]
34. The clinical outcome of Dienogest treatment followed by in vitro fertilization and embryo transfer in infertile women with endometriosis.
Tamura H; Yoshida H; Kikuchi H; Josaki M; Mihara Y; Shirafuta Y; Shinagawa M; Tamura I; Taketani T; Takasaki A; Sugino N
J Ovarian Res; 2019 Dec; 12(1):123. PubMed ID: 31831028
[TBL] [Abstract][Full Text] [Related]
35. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Hormonal Therapies for Decreasing Uterine Volume in Patients with Adenomyosis.
Matsushima T; Akira S; Fukami T; Yoneyama K; Takeshita T
Gynecol Minim Invasive Ther; 2018; 7(3):119-123. PubMed ID: 30254953
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of the relationship between MRI imaging characteristics and clinical symptoms and therapeutic efficacy in adenomyosis patients].
Han XT; Guo HY; Wang F; Gao XR; Liu L; Wang ML
Zhonghua Fu Chan Ke Za Zhi; 2023 May; 58(5):343-350. PubMed ID: 37217341
[No Abstract] [Full Text] [Related]
38. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms.
Pinzauti S; Lazzeri L; Tosti C; Centini G; Orlandini C; Luisi S; Zupi E; Exacoustos C; Petraglia F
Ultrasound Obstet Gynecol; 2015 Dec; 46(6):730-6. PubMed ID: 25728241
[TBL] [Abstract][Full Text] [Related]
39. Uterine disorders and iron deficiency anemia.
Donnez J; Carmona F; Maitrot-Mantelet L; Dolmans MM; Chapron C
Fertil Steril; 2022 Oct; 118(4):615-624. PubMed ID: 36182260
[TBL] [Abstract][Full Text] [Related]
40. Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study.
Chan IS; Hsu TF; Shih YC; Chang YH; Wang PH; Chen YJ
Int J Gynaecol Obstet; 2023 Jun; 161(3):751-759. PubMed ID: 36527263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
